HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USDA Examines Potential Production Regulation Changes To Prevent Powder Formula Contamination

Executive Summary

USDA Food Safety and Inspection Service’s National Advisory Committee on Microbiological Criteria for Foods schedules hearing for 15 November to consider a report from FDA on presence of Cronobacter species bacteria in powder formula products.

You may also be interested in...



US Infant Formula Safety Questions Don’t Include Cronobacter National Reportable Disease Listing

FDA submitted four questions for USDA committee's advice on strengthening prevention of cronobactera contaminations such as problem leading to Abbott facility shutdown earlier in 2022 and supply shortage still affecting US. "High mortality rate of infants infected with cronobacter sakazakii should be enough for consumers expect this issue to receive an urgent response,” Stop Foodborne Illness CEO Mitzi Baum tells FDA and USDA.

Abbott Concludes Former Employees’ Allegations Concerning Michigan Formula Plant ‘Unfounded’

Abbott’s Q3 worldwide sales of formula and other pediatric nutritionals were down 24.8% on reported basis. It plans spending $500m on a new formula facility after finding the US “would benefit from more manufacturing capacity and redundancy.”

US Extends Enforcement Discretion For Infant Formula Production With Guidance For Compliance

Guidance extends through Jan. 6 enforcement discretion for formula products cleared for sales under temporary guidance FDA announced in May. Further extensions possible for firms taking steps toward lawful marketing of products in US, agency says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel